STOK Stoke Therapeutics Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 08 January 2020 Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

   SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Invitae Corporation (NYSE:NVTA) announced that Biogen (NASDAQ:BIIB), Encoded Therapeutics, Neurogene, Praxis Precision

2. 07 January 2020 Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

3. 23 December 2019 Stoke Therapeutics Added to NASDAQ Biotechnology Index

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has

4. 08 December 2019 Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

   STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex Safety findings showed STK-001 to

5. 07 December 2019 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

   New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared to 48% of placebo-treated mice An 80% reduction in the average number of

6. 26 November 2019 Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief

7. 25 November 2019 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

   -- STK-001 is a potential new disease-modifying medicine for the treatment of Dravet syndrome, a severe and progressive form of genetic epilepsy -- Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company

8. 12 November 2019 Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

   Stoke Therapeutics, Inc., (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for

9. 05 November 2019 Stoke Therapeutics to Present at Upcoming Investor Conferences in November

   Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief

10. 30 September 2019 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive

11. 11 September 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added